Oncology Partnering Agreements in Pharma, Biotech and Diagnostics

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Overview of oncology dealmaking

• 2.1. Introduction
• 2.2. The anatomy of oncology partnering
  • 2.2.1. The anatomy of an oncology deal
    • 2.2.1.a. Case study 1: Celgene - Array Biopharma - September 2007
    • 2.2.1.b. Case study 2: Merck - Ariad - July 2007
    • 2.2.1.c. Case study 3: UCB - ImClone - August 2005
• 2.3. Typical partnering terms
  • 2.3.1. Headline deal values
  • 2.3.2. Upfront payments
  • 2.3.3. Milestone payments
  • 2.3.4. Royalties

Chapter 3 - Trends in oncology dealmaking

• 3.1. Introduction
• 3.2. Oncology partnering over the years
• 3.3. Most active oncology dealmakers
• 3.4. Bigpharma oncology dealmaking activity
• 3.5. Bigpharma not active in oncology
• 3.6. Oncology partnering by stage of development
• 3.7. Oncology partnering by deal type
  • 3.7.1. Co-promotion oncology partnering
  • 3.7.2. Option and evaluation oncology partnering
• 3.8. Oncology partnering by disease type
  • 3.8.1. Trends in broad focus oncology partnering

Chapter 4 - Leading oncology deals

• 4.1. Introduction
• 4.2. Top oncology deals by value
• 4.3. Top oncology involving bigpharma

Chapter 5 - Bigpharma oncology deals

• 5.1. Introduction
• 5.2. How to use bigpharma oncology partnering deals
• 5.3. Bigpharma partnering company profiles
  • Abbott
  • Actavis
  • Alcon Labs
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cephalon
  • Chugai
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono
  • Mitsubishi Tanabe
  • Mylan
  • Novartis
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Ratiopharm
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Servier
  • Shire
  • Solvay
  • Takeda
  • Teva
  • UCB
  • Watson
  • Wyeth

Chapter 6 - Oncology dealmaking directory

• 6.1. Introduction
• 6.2. Company A-Z
• 6.3. By stage of development
  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
• 6.4. By deal type
  • Asset and product purchase
  • Collaborative R&D
  • Co-development
  • Co-marketing
  • Co-promotion
  • Development
  • Distribution
  • Joint venture
  • Licensing
  • M&A
  • Manufacturing
  • Marketing
  • Promotion
  • Option
  • Research
  • Supply
• 6.5. By oncology type
  • Bladder
  • Breast
  • Brain
  • Cervical
  • Colorectal
  • Gastrointestinal
  • Head and neck
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple myeloma
  • Ovarian
  • Pancreatic
  • Prostate
  • Solid tumour
  • Broad focus
  • Diagnostics
  • Drug delivery

Chapter 7 - Oncology partnering resource center

• 7.1. Online oncology partnering
• 7.2. Oncology partnering events
• 7.3. Further reading on oncology dealmaking

Appendices

• Appendix 1 - Deal type definitions
• Appendix 2 - Example oncology partnering agreement
• About CurrentPartnering
• Recent titles from CurrentPartnering

• Figure 1: Components of the typical oncology deal structure
• Figure 2: Discovery stage average payment terms
• Figure 3: Average royalty rates payment terms
• Figure 4: Oncology partnering since 2000
• Figure 5: Most active oncology dealmakers 2003-2008
• Figure 6: Bigpharma - top 50 - oncology deals 2003 to 2008
• Figure 7: Inactive oncology dealmakers 2003-2008
• Figure 8: Oncology partnering by stage of development since 2003
• Figure 9: Oncology partnering by deal type since 2003
• Figure 10: Oncology co-promotion deals since 2003
• Figure 11: Oncology option deals since 2003
• Figure 12: Oncology partnering by disease type from 2003
• Figure 13: Trends in broad focus oncology partnering since 2003
• Figure 14: Top oncology deals by value since 2000
• Figure 15: Top 50 oncology deals signed by bigpharma value since 2000
• Figure 16: Online partnering resources
• Figure 17: Forthcoming partnering events
• Figure 18: Deal type definitions
• Figure 19: Oncology partnering between Daiichi Sankyo and ArQule, November 2008